If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 12.66%. Currently, Regeneron Pharmaceut

BenzingaJul 4 23:30

Dupixent, developed by Regeneron (REGN.US) and Sanofi (SNY.US), has been approved in the EU for the treatment of adult patients with chronic obstructive pulmonary disease.

Dupixent is the first new therapy approved for the treatment of COPD in the European Union for over a decade.

Zhitong FinanceJul 4 08:00

Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,183

Morgan Stanley analyst Terence Flynn maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,183.According to TipRanks data, the analyst has a success ra

Futu NewsJul 3 21:32 · Ratings

Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook

TipRanksJul 3 21:25

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characteriz

BenzingaJul 3 20:55

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

Yahoo FinanceJul 3 20:06